Want to see HK:9969 full AI Analyst Report?
Top Page
InnoCare Pharma Ltd.
(9969)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$14.50
▲(23.40% Upside)
Action:Reiterated
Date:06/30/26
The score is primarily supported by a clear profitability inflection and controlled leverage, but is held back by weaker and volatile cash-flow conversion in TTM versus 2025. Technicals are also a headwind with negative MACD and the price below key longer-term moving averages, while valuation (P/E ~26) does not appear especially discounted given modest growth and cash-flow concerns.
Positive Factors
High Profitability
A sustained gross margin near 91% and robust EBIT/net margins indicate durable pricing power and low incremental production cost for core products. This margin profile supports reinvestment in R&D and commercialization, giving the company structural ability to generate profit through product cycles.
Negative Factors
Weak Cash Conversion
A ~60% drop in free cash flow versus 2025 shows profitability is not consistently converting into cash. For a biotech that must fund trials and commercialization, volatile cash conversion raises funding risk and could force dilutive financing or spending cuts if the trend persists.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
A sustained gross margin near 91% and robust EBIT/net margins indicate durable pricing power and low incremental production cost for core products. This margin profile supports reinvestment in R&D and commercialization, giving the company structural ability to generate profit through product cycles.
Read all positive factors
InnoCare Pharma Ltd. (9969) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$21.96B
Dividend YieldN/A
Average Volume (3M)17.45M
Price to Earnings (P/E)29.9
Beta (1Y)1.00
Revenue Growth110.05%
EPS GrowthN/A
CountryHK
Employees1,259
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.40
Shares Outstanding1,496,284,200
10 Day Avg. Volume19,701,315
30 Day Avg. Volume17,452,168
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.52
Price to Sales (P/S)8.47
P/FCF Ratio148.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$19.03Price Target Upside61.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.1
Revenue Forecast (FY)HK$2.29B
InnoCare Pharma Ltd. Business Overview & Revenue Model
Company Description
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a...
How the Company Makes Money
null...
InnoCare Pharma Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.50B | 2.30B | 1.01B | 738.54M | 625.40M | 1.04B |
| Gross Profit | 2.26B | 2.01B | 871.01M | 610.10M | 482.01M | 977.37M |
| EBITDA | 671.33M | 555.89M | -463.49M | -516.55M | -808.28M | 16.23M |
| Net Income | 719.26M | 625.84M | -440.63M | -631.26M | -886.59M | -64.55M |
Balance Sheet | ||||||
| Total Assets | 10.35B | 10.83B | 9.41B | 9.92B | 10.32B | 7.40B |
| Cash, Cash Equivalents and Short-Term Investments | 7.07B | 7.34B | 6.22B | 8.22B | 9.01B | 6.25B |
| Total Debt | 1.80B | 1.61B | 1.27B | 1.35B | 1.25B | 1.27B |
| Total Liabilities | 3.01B | 2.79B | 2.66B | 2.74B | 2.68B | 1.74B |
| Stockholders Equity | 7.32B | 7.73B | 6.73B | 7.15B | 7.60B | 5.60B |
Cash Flow | ||||||
| Free Cash Flow | 29.97M | 130.80M | -443.78M | -926.00M | -935.88M | -11.00K |
| Operating Cash Flow | 105.04M | 199.15M | -365.55M | -671.34M | -565.55M | 167.06M |
| Investing Cash Flow | -905.78M | -358.03M | 1.11B | 666.91M | -1.73B | -1.73B |
| Financing Cash Flow | 118.57M | -32.84M | -285.60M | 1.31M | 3.09B | 2.54B |
InnoCare Pharma Ltd. Technical Analysis
Positive
11.75
Price Trends
12.12
Positive
12.68
Positive
13.37
Positive
Market Momentum
0.78
Negative
59.96
Neutral
58.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9969, the sentiment is Positive. The current price of 11.75 is below the 20-day moving average (MA) of 12.71, below the 50-day MA of 12.12, and below the 200-day MA of 13.37, indicating a bullish trend. The MACD of 0.78 indicates Negative momentum. The RSI at 59.96 is Neutral, neither overbought nor oversold. The STOCH value of 58.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9969.
InnoCare Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$22.41B | 101.26 | 11.29% | ― | 40.78% | 410.73% | |
60 Neutral | HK$21.96B | 29.85 | 10.12% | ― | 110.05% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$18.43B | -12.03 | -24.29% | ― | 8.50% | 35.24% | |
44 Neutral | HK$10.27B | -76.62 | -11.21% | ― | 219.26% | 87.63% | |
44 Neutral | HK$14.58B | -8.95 | -123.74% | ― | -41.32% | -159.81% | |
41 Neutral | HK$8.17B | -18.67 | -64.78% | ― | -33.37% | -344.90% |
* Healthcare Sector Average
HK:9969
InnoCare Pharma Ltd.
13.81
-4.85
-25.99%
HK:9688
Zai Lab Ltd
15.50
-11.70
-43.01%
HK:2171
CARsgen Therapeutics Holdings Ltd.
15.98
-8.87
-35.69%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
50.45
28.95
134.65%
HK:2616
CStone Pharmaceuticals
4.53
-2.04
-31.05%
HK:6855
Ascentage Pharma Group International
35.76
-44.14
-55.24%
InnoCare Pharma Ltd. Corporate Events
InnoCare’s TYK2 Inhibitor Soficitinib Delivers Positive Phase II Results in Non-Segmental Vitiligo
Jul 16, 2026
InnoCare Pharma reported positive topline data from the Phase II portion of its ongoing Phase II/III adaptive trial of soficitinib (ICP-332), an internally discovered next-generation oral TYK2 inhibitor, in adult patients with non-segmental vitili...
InnoCare’s TYK2 Inhibitor Soficitinib Hits Phase III Goal in Atopic Dermatitis
Jul 15, 2026
InnoCare Pharma announced that its Phase III registrational trial of soficitinib, an internally developed next-generation oral TYK2 inhibitor, in adults with moderate-to-severe atopic dermatitis met its primary endpoint with statistically signific...
InnoCare Pharma Grants Performance-Linked RSUs Under 2023 Share Award Scheme
Jun 30, 2026
InnoCare Pharma Limited has granted 1,910,000 restricted share units under its 2023 Share Award Scheme to eight employees, including a member of senior management, equivalent to about 0.11% of its issued share capital. The RSUs carry a purchase pr...
InnoCare Shareholders Approve All Resolutions at 2026 AGM
Jun 16, 2026
InnoCare Pharma Limited reported that all resolutions tabled at its annual general meeting on 16 June 2026 were approved by shareholders via poll, covering financial statements, the 2025 annual and board work reports, and the profit distribution p...
InnoCare Pharma Launches 2026 RMB Share Incentive Scheme with First Grant of Restricted Shares
Jun 16, 2026
InnoCare Pharma has implemented its 2026 RMB Share Incentive Scheme, following shareholder approval at its annual general meeting, and granted 8,000,000 restricted shares to 100 participants. The grant represents about 0.45% of the company’s...
InnoCare Pharma Names New Joint Company Secretary and Secures Listing Rules Waiver
Jun 5, 2026
InnoCare Pharma has appointed senior director of investor relations Yuan Bei as a joint company secretary effective 5 June 2026, alongside existing secretary Lin Sio Ngo. Yuan brings over a decade at the company, board office management experience...
InnoCare’s ITP Drug Filing for Orelabrutinib Accepted by China Regulator
May 28, 2026
InnoCare Pharma said China’s Center for Drug Evaluation has accepted its new drug application for orelabrutinib, a Bruton Tyrosine Kinase inhibitor, for treating primary immune thrombocytopenia in China. The move expands orelabrutinib’...
InnoCare Wins Australian Approval for Lymphoma Drug Orelabrutinib
May 27, 2026
InnoCare Pharma has secured approval from Australia’s Therapeutic Goods Administration for its BTK inhibitor orelabrutinib, branded as HIBRUKA, to treat adult patients with relapsed or refractory mantle cell lymphoma, an aggressive B-cell no...
InnoCare Starts First-in-Human Trial of Oral IL-17 Inhibitor ICP-054
May 13, 2026
InnoCare Pharma has begun dosing the first subject in a Phase 1 clinical trial of ICP-054 (ZB021), a novel oral small-molecule inhibitor targeting IL-17AA and IL-17AF that is being co-developed with Zenas BioPharma. The candidate is designed to of...
InnoCare Pharma Sets 2026 AGM to Approve 2025 Results and Renew Share Issuance Mandate
Apr 24, 2026
InnoCare Pharma has called its annual general meeting for 16 June 2026 in Beijing, where shareholders will review the company’s audited consolidated financial statements and related reports for the year ended 31 December 2025. The agenda als...
InnoCare Pharma Grants RSUs Tied to Revenue and R&D Milestones
Apr 24, 2026
InnoCare Pharma has granted 15,389,245 restricted share units under its 2023 Share Award Scheme to three grantees, including executive directors Dr. Cui and Dr. Zhao and a senior manager, representing about 0.87% of its issued share capital. The R...
InnoCare Pharma Seeks Approval for 2026 RMB Share Incentive Scheme and Wins HKEX Waiver
Apr 24, 2026
InnoCare Pharma plans to adopt a new 2026 RMB Share Incentive Scheme at its upcoming annual general meeting to strengthen its long-term incentive mechanisms and tie employees’ interests more closely to those of shareholders. The scheme aims ...
InnoCare Pharma Issues Unaudited PRC-GAAP Q1 2026 Report for STAR Market Compliance
Apr 23, 2026
InnoCare Pharma Limited has released its unaudited 2026 first-quarter report, prepared under PRC accounting standards for compliance with the STAR Market of the Shanghai Stock Exchange. The report, translated from the Chinese original, has been re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.